Novartis's Big Hopes For Transplant Drug Blown Apart
Iscalimab Not Effective Enough In Preventing Kidney Rejection
Long touted as one of the drugs to watch in the Swiss giant's pipeline, iscalimab's chances of replacing tacrolimus as the standard of care preventing organ rejection in transplant patients have been dealt a hefty blow after a Phase II trial failure.
You may also be interested in...
A Phase II trial of the anti-CD40 drug, which Horizon Therapeutics acquired in early 2021, met its primary endpoint in Sj
The Swiss major’s Cosentyx has succeeded in two trials for the debilitating skin condition but there are concerns that the data may not be sufficient to shift AbbVie’s Humira off the top spot for treatment.
In this week's podcast edition of Scrip's Five Must-Know Things: US industry warns over pricing; a setback for another gene therapy; a Phase II disappointment for Novartis; Actemra shortages cause CAR-T worries; and Sweden's Sobi set to go private.